Environmental

AstraZeneca’s high R&D intensity supports lower-carbon, science-based innovation versus peers, because pharmaceutical value creation depends more on intellectual property than heavy manufacturing inputs.

The company’s environmental profile is strengthened by a relatively asset-light operating model versus diversified healthcare peers, which typically reduces direct emissions and energy intensity.

Peer-relative environmental risk remains moderate because pharmaceutical supply chains still create Scope 3 and waste-management exposure, although these are generally less material than for industrial peers.

Available metrics do not show environmental underinvestment, and the company’s capital allocation appears consistent with long-duration sustainability priorities versus peers.

Social

AstraZeneca’s R&D-to-revenue intensity is materially above many large-cap peers, which supports patient access and medical innovation as a core social contribution.

The company’s social positioning is strengthened by the public-health relevance of its portfolio, because peer comparison in pharmaceuticals favors firms with sustained therapeutic innovation.

No stock-based compensation burden in the provided metrics suggests less dilution pressure than many peers, which can support a more balanced stakeholder profile.

Social risk remains present through product safety, access, and pricing scrutiny, but these are industry-wide issues rather than a clear disadvantage versus peers.

Governance

AstraZeneca’s leverage metrics appear manageable versus peers, which supports governance resilience by reducing balance-sheet pressure that can amplify oversight concerns.

The absence of stock-based compensation in the provided data indicates cleaner capital discipline than many peers, where equity-based pay can weaken alignment.

High R&D intensity can create governance complexity, but in pharmaceuticals it is also a sign of disciplined long-term allocation relative to peers.

No major governance controversy is indicated in the provided inputs, so the company appears broadly aligned with large-cap pharma governance standards.

Overall Score

AstraZeneca screens as a strong ESG performer versus peers, led by high R&D-driven social and environmental positioning with no clear structural governance weakness.

Score Driver: High R&D Intensity Relative To Peers